Advanced lung adenocarcinoma
Conditions
Interventions
Experimental group:Tumor infiltrating lymphocytes treatment
Control group:Conventional chemotherapy or maintenance treatment
Sponsors
Huadong Hospital Affiliated to Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years, male or female; 2. Patients with pathologically confirmed lung cancer, stage IIIC or IV with failed treatment with PD-1 monoclonal antibody or EGFR-TKI; 3. Patients with at least one assessable lesion according to RECIST v1.1 standard; 4. The physical condition is evaluated as ECOG 0-2; 5. Normal functions of organs and bone marrow are defined as follows: leukocyte count >= 9 g/dl (without blood transfusion), neutrophil count >= 2100/UL, platelet count >= 100000/UL, total bilirubin = 60 ml/min, and the urea nitrogen is 6 months; 10. There is no primary tumor in other parts before treatment, or there is primary tumor in other parts, but it has been controlled for more than 5 years; 11. Patients had good dependence, voluntarily joined the study and signed informed consent form (ICF).
Exclusion criteria
Exclusion criteria: 1. Severe allergy to TIL treatment or allergic reaction to other similar biological drug components; 2. Participate in other clinical trials at the same time; 3. Participated in other clinical trials in the past 30 days; 4. Pregnancy, lactation or fertility without contraceptive measures; 5. Drug abuse and other drug addiction, long-term alcoholism, and AIDS patients; 6. Patients with basic diseases, abnormal coagulation function, poor general conditions and other patients who cannot tolerate neoadjuvant treatment and surgical treatment; 7. Other patients considered by the attending physician as unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate;Overall survival; | — |
Countries
China
Contacts
Public ContactGao Wen
Huadong Hospital Affiliated to Fudan University
Outcome results
None listed